stoxline Quote Chart Rank Option Currency Glossary
Lifecore Biomedical, Inc. (LFCR)
5.58  -0.04 (-0.71%)    05-28 16:00
Open: 5.65
High: 5.6799
Volume: 269,398
Pre. Close: 5.62
Low: 5.53
Market Cap: 170(M)
Technical analysis
2024-05-28 3:53:26 PM
Short term     
Mid term     
Targets 6-month :  7.69 1-year :  8.45
Resists First :  6.58 Second :  7.23
Pivot price 6.05
Supports First :  5.53 Second :  4.6
MAs MA(5) :  5.73 MA(20) :  6.15
MA(100) :  6.77 MA(250) :  7.56
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  3.7 D(3) :  8.8
RSI RSI(14): 34.8
52-week High :  11.46 Low :  4.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LFCR ] has closed above bottom band by 17.5%. Bollinger Bands are 12.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.8 - 5.84 5.84 - 5.86
Low: 5.51 - 5.55 5.55 - 5.59
Close: 5.56 - 5.63 5.63 - 5.68
Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Headline News

Wed, 22 May 2024
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Australia

Thu, 16 May 2024
Lifecore Biomedical (NASDAQ:LFCR) Shares Down 2.1% - Defense World

Fri, 03 May 2024
Here’s Why Laughing Water Capital Invested in Lifecore Biomedical (LFCR) - Insider Monkey

Sun, 21 Apr 2024
Lifecore Stock: Getting Closer To Massive Improvements In Earnings Power (NASDAQ:LFCR) - Seeking Alpha

Fri, 19 Apr 2024
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to ... - PR Newswire

Thu, 11 Apr 2024
Do You Believe in the Upside Trajectory of Lifecore Biomedical (LFCR)? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 31 (M)
Shares Float 18 (M)
Held by Insiders 4.5 (%)
Held by Institutions 74.5 (%)
Shares Short 1,980 (K)
Shares Short P.Month 1,790 (K)
Stock Financials
EPS -2.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.15
Profit Margin -96.5 %
Operating Margin -7.7 %
Return on Assets (ttm) -4.7 %
Return on Equity (ttm) -104.6 %
Qtrly Rev. Growth 20.7 %
Gross Profit (p.s.) 0
Sales Per Share 3.38
EBITDA (p.s.) -0.33
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow 16 (M)
Stock Valuations
PE Ratio -2.61
PEG Ratio -0.9
Price to Book value -39.79
Price to Sales 1.64
Price to Cash Flow -9.76
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android